Ryan Allway June 16th, 2022 News, Top News CFO of GVB Biopharma to Expand Role, Become CFO of 22nd Century Group Integration of GVB Biopharma Proceeding at a Rapid Pace BUFFALO, N.Y., June 16, 2022 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company), dedicated to... Read more
Isracann Biosciences Signs Definitive Agreement to Acquire Natural Health Medicine Developer
March 28, 2022
Ryan Allway March 28th, 2022 News, Top News VANCOUVER, British Columbia, March 28, 2022 (GLOBE NEWSWIRE) — Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that, further to the Company’s news release dated February 23, 2022, it has entered into a definitive... Read more
Ryan Allway March 24th, 2022 News, Top News Cash balance of $18.9 million as of December 31, 2021 Signed out-licensing deal worth $42.7 million with Ewopharma Phase III psoriasis topline data expected Q2 2022 Namodenoson induced complete response and cleared all cancer lesions in advanced liver cancer patient in Can-Fite’s... Read more
Eco Innovation Group Receives Notice of Allowance from USPTO Covering Glytech, LLC Supercritical Plant Extraction Technology
March 17, 2022
Ryan Allway March 17th, 2022 News, Top News VAN NUYS, Calif., March 17, 2022 /PRNewswire/ — Eco Innovation Group, Inc. (OTC: ECOX) (“ECOX” or the “Company”), an innovative company aggregating investments in new technologies that promote environmental and social well-being and the advancement of green energy solutions, today announced that it... Read more
Nova Mentis Announces Closing of Non-Brokered Financing
March 15, 2022
Ryan Allway March 15th, 2022 Psychedelics, Top News VANCOUVER, BC, March 15, 2022 /CNW/ – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biotechnology company and global leader in first-in-class psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce that it has completed a non-brokered private... Read more
Bright Minds Biosciences Announces Successful Completion of 28-Day Toxicology Studies and Advancement to First-in-Human Clinical Trial
March 14, 2022
Ryan Allway March 14th, 2022 Psychedelics, Top News VANCOUVER, British Columbia, March 14, 2022 (GLOBE NEWSWIRE) — Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today... Read more
Applied DNA Announces Pricing of $4.2 Million Registered Direct Offering
February 22, 2022
Ryan Allway February 22nd, 2022 News, Top News STONY BROOK, N.Y., February 22, 2022–(BUSINESS WIRE)–Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, announced today that it has entered into a securities purchase agreement with an institutional investor, providing for the... Read more
BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect and Pharmacokinetics Data for BETR-001
January 18, 2022
Ryan Allway January 18th, 2022 Psychedelics VANCOUVER, British Columbia, Jan. 18, 2022 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of 2nd-generation non-hallucinogenic psychedelic analogs for the treatment of neuropsychological disorders, is pleased to... Read more
Ryan Allway January 13th, 2022 VERNON, BC, Jan. 13, 2022 /CNW/ – Doseology Sciences Inc. (CSE: MOOD) (“Doseology” or the “Company”) announces the appointment of Maryam Marissen as Chief Executive Officer and Director, effective immediately. Outgoing interim CEO and co-founder Daniel Vice will remain involved with the Company as an independent director. Doseology is a British Columbia-based, diversified... Read more
MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC
January 4, 2022
Ryan Allway January 4th, 2022 Psychedelics – Last subject completed study in late 2021 with topline results expected in early 2022 – – Results to inform design of Phase 2a study in individuals undergoing supervised opioid withdrawal – NEW YORK, Jan. 4, 2022 /CNW/ — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED),... Read more
